Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MED.0000000000000254 http://scihub22266oqcxt.onion/10.1097/MED.0000000000000254 C4896735!4896735!26978733     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Endocrinol+Diabetes+Obes 2016 ; 23 (3): 279-90 Nephropedia Template TP {{tp|p=26978733|t=2016. Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer |pdf=|usr=}}{{26978733}} gab.com Text Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer JO: Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=26978733 #FOAvip PURPOSE OF REVIEW: Understanding the mechanisms by which castration-resistant prostate cancer progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancer?s androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in castration-resistant prostate cancer, with a particular focus on the unique characteristics of drugs in various stages of clinical development. RECENT FINDINGS: The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively-active splice variant forms of the protein, androgen receptor degraders, and bromodomain/BET inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. SUMMARY: Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alteration. Twit Text FOAVip Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer ????Curr Opin Endocrinol Diabetes Obes http://www.kidney.de/pget.php?&tw=1&pmid=26978733 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26978733 #FOAvip English Wikipedia <ref>{{Cite pmid|26978733}}</ref> Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer #MMPMID26978733 Teply BA; Antonarakis ES Curr Opin Endocrinol Diabetes Obes 2016[Jun]; 23 (3): 279-90 PMID26978733show ga PURPOSE OF REVIEW: Understanding the mechanisms by which castration-resistant prostate cancer progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancer?s androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in castration-resistant prostate cancer, with a particular focus on the unique characteristics of drugs in various stages of clinical development. RECENT FINDINGS: The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively-active splice variant forms of the protein, androgen receptor degraders, and bromodomain/BET inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. SUMMARY: Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alteration. äNovel mechanism-based therapeutics for androgen axis blockade in castr(epmc).pdf DeepDyve Pubget Overpricing